Researchers examined 41,663 patients with C. Diff who were hospitalized between January 2013 and May 2014. Researchers excluded patients who had C. Diff on hospital admission. Of the remaining patients, 17,302 received at least one dose of a PPI and 24,092 did not receive any PPI.
Sixty-five of the 17,302 patients in the PPI group later developed C. Diff in the hospital, as compared with only 14 of the 24,092 patients in the control group. In the PPI group, 0.21 percent of patients met the definition of severe C. Diff compared with 0.03 percent of control group patients. When only evaluating patients who developed severe-complicated C. Diff, there were 22 cases in the PPI group and two cases in the control group.
More articles on quality:
UV lamps can help keep computer keyboards sterile, study shows
New study identifies why MRSA kills flu patients
Zika outbreak spurs HHS to declare public health emergency in Puerto Rico
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
